{
    "id": "9134216",
    "text": "Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system. == Current status == Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo. == References == Category:Monoclonal antibodies Category:Abandoned drugs ",
    "title": "Pexelizumab"
}